Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT4QPUL)

• DTT Name: Antithrombin-III (ATIII) DTT Info
• Gene Name: SERPINC1

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ardeparin	DMYRX8B	Deep vein thrombosis	BD71	Approved	[1]
Heparin Calcium	DMEVXY6	Coagulation defect	3B10.0	Approved	[1]
Heparin Sodium	DM9KHZL	Coagulation defect	3B10.0	Approved	[2]
Sulodexide	DMNUC42	Tinnitus	MC41	Approved	[3]

9 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Heparin low molecular weight	DMGFULM	Thrombosis	DB61-GB90	Phase 3	[4]
KW-3357	DMP3GI2	Coagulation defect	3B10.0	Phase 3	[5]
Unfractionated heparin	DMCWM03	Thrombosis	DB61-GB90	Phase 3	[6]
M118	DML0I2Z	Acute coronary syndrome	BA41	Phase 2	[7]
O-desulfated heparin	DMJL4A7	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
PMX-60056	DMWT73D	Coagulation defect	3B10.0	Phase 2	[9]
MER-102	DME18UM	Thrombosis	DB61-GB90	Phase 1	[10]
OPK-0018	DMLUYAJ	Asthma	CA23	Phase 1	[2]
RO-14	DM95F8B	Phlebothrombosis	GB90.3	Phase 1	[11]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deligoparin sodium	DMXKWAL	Ulcerative colitis	DD71	Discontinued in Phase 3	[2]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[12]
Heparin Pentasaccharide	DMY16VG	Discovery agent	N.A.	Investigative	[12]
LHD-4	DMKI70D	Solid tumour/cancer	2A00-2F9Z	Investigative	[2]
N-Formylmethionine	DM7GBDX	Discovery agent	N.A.	Investigative	[12]
Org-36764	DM4SFKW	Discovery agent	N.A.	Investigative	[13]
PNU-87663	DM6SZVE	Discovery agent	N.A.	Investigative	[14]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
• [3] Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
• [4] Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
• [5] Company report (kyowa-kirin)
• [6] Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
• [7] Clinical pipeline report, company report or official report of Momentapharma.
• [8] Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
• [9] Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.
• [10] Clinical pipeline report, company report or official report of Merrion's GIPET technology.
• [11] Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10.
• [12] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [13] Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities. Thromb Haemost. 2000 Oct;84(4):611-20.
• [14] List of drugs in development for neurodegenerative diseases.Update June 2004.Neurodegener Dis.2004;1(2-3):113-52.